Warner Chilcott acquires Dong-A's udenafil for US
This article was originally published in Scrip
Dong-A PharmTechhas licensed its erectile dysfunction product udenafil exclusively to Warner Chilcottfor development and marketing in the US. The oral PDE5 inhibitor was approved as Zydena in South Korea in 2005 and in Russia last year, and Dong-A has already completed a Phase II US development programme. The South Korean firm will receive undisclosed up-front and milestone payments from Warner Chilcott, which already markets a range of oral contraceptives and women's health products.